Molnupiravir reduces long-term COVID-19 symptoms but shows limited impact on hospitalizations

Molnupiravir treatment for COVID-19 shows modest long-term benefits, reducing symptoms and improving well-being at three and six months. However, the differences were small, with no impact on hospitalization rates.

It was a turbulent year for the business of health tech. 3 trends to watch in 2024

Is it too early to say that the health tech boom feels like a million years ago? In 2020 and 2021, the jolt of pandemic

January 2, 2024

Vaping increases susceptibility to COVID-19 infection, study finds

Vapers are susceptible to infection by SARS-CoV-2, the virus that spreads COVID-19 and continues to infect people around the world, a University of California, Riverside,

February 27, 2024

Expert consensus and guidance for integrating discussions of racism in pediatric care

Extensive research shows the link between exposure to racism during childhood and adolescence and increased risks of depression and metabolic health issues, such as obesity,

June 21, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.